-
Mashup Score: 0The Cancer News Daily - 2 year(s) ago
The latest in cancer medicine and translational research by Wafik El-Deiry MDPhD
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3Aneuploidy May Help Tumors Become Resistant to Treatment - 3 year(s) ago
Aneuploidy—when cells have too many or too few chromosomes—may be common in cancer cells because it helps them develop resistance to drugs like chemotherapy and targeted therapies, two new studies suggest. The cancer cells that thrived tended to have the same pattern of extra or missing chromosomes, they found.
Source: National Cancer InstituteCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 6Report Details Alcohol’s Global Cancer Burden - 3 year(s) ago
Nearly 750,000 cases of cancer diagnosed worldwide in 2020, or 4%, can be attributed to alcohol consumption, according to a new World Health Organization (WHO) study. While heavy drinking accounted for the most cases, light and moderate drinking accounted for more than 100,000 of those cases.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 8PSMA Radiopharmaceutical Effective against Prostate Cancer - 3 year(s) ago
A drug called 177Lu-PSMA-617 may be a new option for treating advanced prostate cancer. In a large clinical trial called VISION, participants who received 177Lu-PSMA-617—a type of drug called a radiopharmaceutical—along with standard treatments lived longer than those who received only standard therapies.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 14New-Onset Diabetes: An Early Sign of Pancreatic Cancer? - 3 year(s) ago
Numerous studies have pointed to a link between new-onset diabetes and pancreatic cancer. Now, several large NCI-supported studies are testing ways to pick out those people whose diabetes might be a sign of early pancreatic cancer, when treatments may be more effective.
Source: National Cancer InstituteCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 13New-Onset Diabetes: An Early Sign of Pancreatic Cancer? - 3 year(s) ago
Numerous studies have pointed to a link between new-onset diabetes and pancreatic cancer. Now, several large NCI-supported studies are testing ways to pick out those people whose diabetes might be a sign of early pancreatic cancer, when treatments may be more effective.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Testing Novobiocin in PARP Inhibitor-Resistant Cancers - 3 year(s) ago
The antibiotic novobiocin showed promise as a treatment for cancers with BRCA mutations that have become resistant to PARP inhibitors. It will soon be tested in NCI-supported clinical trials. The drug inhibits a protein called Pol theta. Another Pol theta inhibitor, ART558, was effective in mice with resistant tumors.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 5Sacituzumab Earns Regular FDA Approval for TNBC - 3 year(s) ago
Sacituzumab govitecan (Trodelvy) now has regular FDA approval for people with locally advanced or metastatic triple-negative breast cancer (TNBC), including those with brain metastases. The update follows last year’s accelerated approval of the drug for people with TNBC.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6Tebentafusp Improves Survival in Advanced Uveal Melanoma - 3 year(s) ago
The results of a large clinical trial show that the investigational immunotherapy tebentafusp, a bispecific fusion protein, improves overall survival in patients with metastatic uveal melanoma. There is no standard treatment for the disease and, once it has spread, many patients do not survive for a year.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 15AMBRA1 Protein Found to Be an Important Tumor Suppressor - 3 year(s) ago
Researchers have shown that the loss of a protein called AMBRA1 can cause tumors to form in mice and is linked with worse outcomes in some human tumors. A lack of AMBRA1 may make some tumors resistant to CDK4/6 inhibitor drugs. The new research may lead to strategies for re-sensitizing cancer cells to these drugs.
Source: National Cancer InstituteCategories: Healthcare Professionals, Latest HeadlinesTweet
The latest The Cancer News Daily! https://t.co/Oyw1AeFdVR Thanks to @cure_magazine @Nature @Aiims1742 #ncicancercurrentsblog #prostatecancer